Chardan Capital Weighs in on EYPT FY2025 Earnings

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) – Research analysts at Chardan Capital issued their FY2025 earnings per share (EPS) estimates for EyePoint Pharmaceuticals in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst D. Gataulin anticipates that the company will earn ($2.92) per share for the year. Chardan Capital currently has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for EyePoint Pharmaceuticals’ current full-year earnings is ($2.13) per share.

A number of other analysts also recently commented on the stock. Citigroup began coverage on shares of EyePoint Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating and a $33.00 price objective for the company. StockNews.com raised EyePoint Pharmaceuticals to a “sell” rating in a report on Friday, March 14th. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, EyePoint Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $26.63.

EyePoint Pharmaceuticals Trading Down 2.5 %

NASDAQ:EYPT opened at $5.91 on Thursday. The company has a market cap of $406.19 million, a P/E ratio of -2.96 and a beta of 1.41. EyePoint Pharmaceuticals has a twelve month low of $5.54 and a twelve month high of $23.65. The company’s 50-day moving average price is $6.82 and its 200-day moving average price is $8.24.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.54) by ($0.10). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The firm had revenue of $11.60 million during the quarter, compared to analyst estimates of $11.02 million.

Hedge Funds Weigh In On EyePoint Pharmaceuticals

Hedge funds have recently modified their holdings of the business. RA Capital Management L.P. acquired a new position in EyePoint Pharmaceuticals during the fourth quarter worth $23,705,000. TCG Crossover Management LLC raised its holdings in EyePoint Pharmaceuticals by 287.3% in the fourth quarter. TCG Crossover Management LLC now owns 3,572,335 shares of the company’s stock valued at $26,614,000 after acquiring an additional 2,650,000 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of EyePoint Pharmaceuticals by 51.7% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company’s stock worth $42,838,000 after acquiring an additional 1,958,580 shares in the last quarter. Federated Hermes Inc. increased its holdings in shares of EyePoint Pharmaceuticals by 92.7% in the 4th quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company’s stock valued at $27,620,000 after acquiring an additional 1,783,765 shares during the last quarter. Finally, Suvretta Capital Management LLC raised its position in shares of EyePoint Pharmaceuticals by 31.1% during the 4th quarter. Suvretta Capital Management LLC now owns 6,783,091 shares of the company’s stock worth $50,534,000 after acquiring an additional 1,607,268 shares in the last quarter. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.